Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-02-04T02:50:40.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine

Published online by Cambridge University Press:  28 June 2021

Jihyun Park Open the ORCID record for Jihyun Park [Opens in a new window] ,
Dona R. Brekke  and
Andras Bratincsak Open the ORCID record for Andras Bratincsak [Opens in a new window]
Jihyun Park
Affiliation:
Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
Dona R. Brekke
Affiliation:
Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA Pediatric Cardiology, Hawaii Pacific Health Medical Group, Honolulu, Hawaii, USA
Andras Bratincsak*
Affiliation:
Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA Pediatric Cardiology, Hawaii Pacific Health Medical Group, Honolulu, Hawaii, USA
*
Author for correspondence: Andras Bratincsak, MD, Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii, 1319 Punahou Street, Suite 950, Honolulu, Hawaii, USA. Tel: 808-983-8933; Fax: 808-957-9770. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Two adolescent males presented within 3 days after the first and second dose of the BNT162b2 vaccine with chest pain. Elevated troponin levels, ST segment elevation, and enhancement of the myocardium in cardiac MRI suggested myocarditis. Left ventricular function remained normal, symptoms resolved, and patients were discharged in 4 days. BNT162b2 vaccine may be associated with self-limited myocarditis in youth.

Keywords

myocarditisST segment elevationtroponinCOVID-19vaccine
Type
Brief Report
Information
Cardiology in the Young , Volume 32 , Issue 1 , January 2022 , pp. 146 - 149
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Committee on Infectious Diseases. COVID-19 vaccines in children and adolescents. Pediatrics 2021; e2021052336.Google Scholar
Wallace, M, Woodworth, KR, Gargano, JW, et al. The Advisory committee on immunization practices’ Interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years — United States, May 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 749–752.CrossRefGoogle ScholarPubMed
García, JB, Ortega, PP, Fernández, JAB, et al. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol 2021; S1885-5857(21)00133-X.Google Scholar
Advisory Committee on Immunization Practices. COVID-19 VaST Work Group Technical Report – May 17, 2021. Centers for Disease Control and Prevention Vaccine Safety Technical Work Group Reports 2021 May.Google Scholar
Mei, R, Raschi, E, Forcesi, E et al. Myocarditis and Pericarditis after Immunization: gaining Insights through the Vaccine Adverse Event Reporting System. Int J Cardiol 2018; 273: 183–186.CrossRefGoogle ScholarPubMed
Kadali, RAK, Janagama, R, Peruru, S et al. Side effects of BNT162b2 MRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis 2021; 106: 376–381.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Clinical considerations: Myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. Centers for Disease Control and Prevention 2021 May.Google Scholar
State of Hawaii Department of Health, Disease Outbreak Control Division COVID-19 Response. Hawaii COVID-19 Data. State of Hawaii Department of Health, Disease Outbreak Control Division 2021 June.Google Scholar
Maroon, BJ, Udelson, JE, Bonow, RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: task Force 3: hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis. Circulation 2015; 132: e273–e280.10.1161/CIR.0000000000000239CrossRefGoogle Scholar
Supplementary material: Image

Park et al. supplementary material

Park et al. supplementary material

Download Park et al. supplementary material(Image)
Image 12.5 MB